| NCT06397872 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function | ENROLLING_BY_INVITATION | PHASE1 | 2024-03-05 | 2024-12-31 | 2024-11-30 |
| NCT05500222 | A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-08-26 | 2027-01 | 2026-12 |
| NCT04951219 | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | ACTIVE_NOT_RECRUITING | PHASE3 | 2021-07-09 | 2026-04 | 2026-03 |
| NCT04197479 | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients | COMPLETED | PHASE3 | 2019-12-16 | 2023-01-06 | 2023-01-06 |
| NCT04671069 | Drug Interaction Study of MGL-3196 With Clopidogrel | COMPLETED | PHASE1 | 2019-07-26 | 2019-09-14 | 2019-08-30 |
| NCT03900429 | A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis | ACTIVE_NOT_RECRUITING | PHASE3 | 2019-03-28 | 2028-01 | 2028-01 |
| NCT04671056 | Drug Interaction Study of MGL-3196 With Pioglitazone | COMPLETED | PHASE1 | 2018-11-09 | 2019-01-05 | 2018-12-11 |
| NCT04643795 | Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects | COMPLETED | PHASE1 | 2018-10-25 | 2021-08-04 | 2021-08-04 |
| NCT03413124 | Bioavailability Study of MGL-3196 Tablets Compared to Capsules | COMPLETED | PHASE1 | 2018-02-05 | 2018-03-13 | 2018-02-17 |
| NCT03220165 | Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196 | COMPLETED | PHASE1 | 2017-08-06 | 2017-09-03 | 2017-09-03 |
| NCT03038022 | Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) | COMPLETED | PHASE2 | 2017-02-09 | 2018-01-15 | 2017-12-18 |
| NCT02912260 | Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) | UNKNOWN | PHASE2 | 2016-09 | 2018-04 | 2017-10 |
| NCT02749578 | Drug Interaction Study of MGL-3196 With Atorvastatin | COMPLETED | PHASE1 | 2016-04 | 2016-05 | 2016-05 |
| NCT02542969 | Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin | COMPLETED | PHASE1 | 2015-09 | 2015-10 | 2015-10 |
| NCT01519531 | Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects | COMPLETED | PHASE1 | 2012-01 | 2012-11 | 2012-11 |
| NCT01367873 | Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects | COMPLETED | PHASE1 | 2011-06 | 2011-10 | 2011-10 |